Advertisement

Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection

  • Neven PapićEmail author
  • Fabijan Jelovčić
  • Marko Karlović
  • Lorna Stemberger Marić
  • Adriana Vince
Original Article

Abstract

Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea while nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The aim of this study was to determine whether NAFLD increases susceptibility to CDI. A retrospective cohort study included patients ≥ 65 years, treated with antimicrobial therapy ≥ 24 h, and hospitalized ≥ 72 h in a 36-month period. Three-hundred fourteen patients were included; 83 with NAFLD and 231 controls. Except for diabetes mellitus (37.35% vs. 25.11%, p = 0.0462) and obesity (18.07% vs. 8.23%, p = 0.0218) that were more frequent in NAFLD group, there were no differences in other comorbidities, hospital admissions, antibiotic therapy within 3 months, prescription, and duration of antibiotic therapy. Fourteen (16.9%) patients with NAFLD and 17 (7.4%) in control group developed in-hospital CDI (p = 0.0156). The Charlson Age-Comorbidity Index > 6 (OR 4.34, 95%CI 1.39–13.57), hospital admission within 3 months (OR 7.14, 95%CI 2.33–21.83), serum albumins < 28 g/L (OR 3.15, 95%CI 1.04–9.53), NAFLD (OR 3.27, 95%CI 1.04–10.35), eGFR < 40 (OR 4.89, 95%CI 1.61–14.88), treatment with piperacillin/tazobactam (OR 4.86, 95%CI 1.59–14.83), and carbapenems (OR 3.99, 95%CI 1.28–12.40) were independently associated with CDI. Our study identified NAFLD as an independent predictor of CDI.

Keywords

NAFLD NASH Clostridioides difficile associated disease Healthcare-associated diarrhea Nosocomial infections 

Notes

Author contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Neven Papić, Lorna Stemberger Marić, Fabijan Jelovčić, and Marko Karlović. The first draft of the manuscript was written by Neven Papić, Fabijan Jelovčić, and Marko Karlović and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional ethical committee (Ethical committee University Hospital for Infectious Diseases Zagreb) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK, Emerging Infections Program Healthcare-Associated I, Antimicrobial Use Prevalence Survey T (2014) Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370(13):1198–1208.  https://doi.org/10.1056/NEJMoa1306801 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Crobach MJT, Vernon JJ, Loo VG, Kong LY, Pechine S, Wilcox MH, Kuijper EJ (2018) Understanding Clostridium difficile colonization. Clin Microbiol Rev 31(2).  https://doi.org/10.1128/CMR.00021-17
  3. 3.
    Czepiel J, Drozdz M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, Goldman S, Wultanska D, Garlicki A, Biesiada G (2019) Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis 38(7):1211–1221.  https://doi.org/10.1007/s10096-019-03539-6 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Dotson KM, Aitken SL, Sofjan AK, Shah DN, Aparasu RR, Garey KW (2018) Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect 146(9):1101–1105.  https://doi.org/10.1017/S0950268818001036 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Yan D, Chen Y, Lv T, Huang Y, Yang J, Li Y, Huang J, Li L (2017) Clostridium difficile colonization and infection in patients with hepatic cirrhosis. J Med Microbiol 66(10):1483–1488.  https://doi.org/10.1099/jmm.0.000596 CrossRefPubMedGoogle Scholar
  6. 6.
    Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1):328–357.  https://doi.org/10.1002/hep.29367 CrossRefPubMedGoogle Scholar
  7. 7.
    European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388–1402.  https://doi.org/10.1016/j.jhep.2015.11.004 CrossRefGoogle Scholar
  8. 8.
    Sharpton SR, Ajmera V, Loomba R (2019) Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin Gastroenterol Hepatol 17(2):296–306.  https://doi.org/10.1016/j.cgh.2018.08.065 CrossRefPubMedGoogle Scholar
  9. 9.
    Jayakumar S, Loomba R (2019) Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther 50(2):144–158.  https://doi.org/10.1111/apt.15314 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F (2008) AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 7(4):350–357CrossRefGoogle Scholar
  11. 11.
    Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver D (2012) Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 12:2.  https://doi.org/10.1186/1471-230X-12-2 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612.  https://doi.org/10.7326/0003-4819-150-9-200905050-00006 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Crobach MJ, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, Wilcox MH, Kuijper EJ (2016) European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 22(Suppl 4):S63–S81.  https://doi.org/10.1016/j.cmi.2016.03.010 CrossRefPubMedGoogle Scholar
  14. 14.
    McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH (2018) Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66(7):e1–e48.  https://doi.org/10.1093/cid/cix1085 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nseir W, Amara A, Farah R, Ahmad HS, Mograbi J, Mahamid M (2019) Non-alcoholic fatty liver disease is associated with recurrent urinary tract infection in premenopausal women independent of metabolic syndrome. Isr Med Assoc J 21(6):386–389PubMedGoogle Scholar
  16. 16.
    Nseir W, Artul S, Nasrallah N, Mahamid M (2016) The association between primary bacteremia of presumed gastrointestinal origin and nonalcoholic fatty liver disease. Dig Liver Dis 48(3):343–344.  https://doi.org/10.1016/j.dld.2015.10.004 CrossRefPubMedGoogle Scholar
  17. 17.
    Nseir WB, Mograbi JM, Amara AE, Abu Elheja OH, Mahamid MN (2019) Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia. QJM 112(2):95–99.  https://doi.org/10.1093/qjmed/hcy227 CrossRefPubMedGoogle Scholar
  18. 18.
    Kistangari G, Lopez R, Shen B (2017) Frequency and risk factors of Clostridium difficile infection in hospitalized patients with pouchitis: a population-based study. Inflamm Bowel Dis 23(4):661–671.  https://doi.org/10.1097/MIB.0000000000001057 CrossRefPubMedGoogle Scholar
  19. 19.
    Shakov R, Salazar RS, Kagunye SK, Baddoura WJ, DeBari VA (2011) Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control 39(3):194–198.  https://doi.org/10.1016/j.ajic.2010.08.017 CrossRefPubMedGoogle Scholar
  20. 20.
    Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D (2004) Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 171(1):33–38CrossRefGoogle Scholar
  21. 21.
    Chandradas S, Khalili H, Ananthakrishnan A, Wayman C, Reidel W, Waalen J, Konijeti GG (2018) Does obesity influence the risk of Clostridium difficile infection among patients with ulcerative colitis? Dig Dis Sci 63(9):2445–2450.  https://doi.org/10.1007/s10620-018-5108-2 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bishara J, Farah R, Mograbi J, Khalaila W, Abu-Elheja O, Mahamid M, Nseir W (2013) Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis 57(4):489–493.  https://doi.org/10.1093/cid/cit280 CrossRefPubMedGoogle Scholar
  23. 23.
    Mulki R, Baumann AJ, Alnabelsi T, Sandhu N, Alhamshari Y, Wheeler DS, Perloff S, Katz PO (2017) Body mass index greater than 35 is associated with severe Clostridium difficile infection. Aliment Pharmacol Ther 45(1):75–81.  https://doi.org/10.1111/apt.13832 CrossRefPubMedGoogle Scholar
  24. 24.
    Hopkins MJ, Macfarlane GT (2002) Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 51(5):448–454.  https://doi.org/10.1099/0022-1317-51-5-448 CrossRefPubMedGoogle Scholar
  25. 25.
    Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Cales P, Diehl AM (2016) The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63(3):764–775.  https://doi.org/10.1002/hep.28356 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Mullane KM, Winston DJ, Nooka A, Morris MI, Stiff P, Dugan MJ, Holland H, Gregg K, Adachi JA, Pergam SA, Alexander BD, Dubberke ER, Broyde N, Gorbach SL, Sears PS (2019) A randomized, placebo-controlled trial of fidaxomicin for prophylaxis of Clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation. Clin Infect Dis 68(2):196–203.  https://doi.org/10.1093/cid/ciy484 CrossRefPubMedGoogle Scholar
  27. 27.
    Papic N, Maric LS, Vince A (2018) Efficacy of oral vancomycin in primary prevention of Clostridium Difficile infection in elderly patients treated with systemic antibiotic therapy. Infect Dis (Lond) 50(6):483–486.  https://doi.org/10.1080/23744235.2018.1425551 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Viral HepatitisUniversity Hospital for Infectious Diseases ZagrebZagrebCroatia
  2. 2.School of MedicineUniversity of ZagrebZagrebCroatia
  3. 3.School of Dental MedicineUniversity of ZagrebZagrebCroatia

Personalised recommendations